Global Information
회사소개 | 문의 | 위시리스트

암 치료제 파이프라인 분석

Oncology Pipeline Analytics

리서치사 Greystone Research Associates
발행일 2018년 12월 상품 코드 758382
페이지 정보 영문 195 Pages, 125 Charts and visualizations
가격
US $ 2,850 ₩ 3,405,000 PDF by E-mail (Single User License)
US $ 4,500 ₩ 5,377,000 PDF by E-mail (Site License)
US $ 6,500 ₩ 7,766,000 PDF by E-mail (Corporate License)


암 치료제 파이프라인 분석 Oncology Pipeline Analytics
발행일 : 2018년 12월 페이지 정보 : 영문 195 Pages, 125 Charts and visualizations

암 치료제 파이프라인(Oncology Pipeline)에 대해 조사했으며, 주요 개발 기업과 활동 및 암 치료제 시장에서의 지위, 암 파이프라인 개발 시장 구도를 촉진하는 주요인, 현재의 암 임상시험 시장 규모, 시장 점유율 리더 및 시장 점유율 전망, 시장에 영향을 미치는 경제·기술·규제 요인 등에 대해 정리했습니다.

1. 주요 요약

2. 암 치료에서 Drug Discovery의 과제

  • 생물학적 약제
  • 바이오시밀러
  • 소분자 약제

3. 개발 단계의 주요 암 치료제

  • atezolizumab
  • PD-1 & PD-L1
  • durvalumab
  • HDAC Inhibitors
  • nivolumab
  • BET Inhibitors
  • CAR-T cell therapy
  • Oncolytic Viruses
  • STAT3 Inhibitors
  • carbozantinib
  • Anti-LAG3 mAb
  • BTK Inhibitor
  • PARP Inhibitors

4. 암 치료제 임상시험 활동 : 스폰서 및 질병 부문별

  • 방광암
  • 뇌종양
  • 유방암
  • 대장암
  • 위암
  • 두경부암
  • 혈액암
  • 간암
  • 신장암
  • 백혈병
  • 폐암
  • 림프종
  • 다발성 골수종
  • 난소암
  • 췌장암
  • 전립선암
  • 육종
  • 피부암
  • 고형종양
  • 기타 암

5. 기업 개요

LSH 19.01.09

Converging Factors Driving the Oncology Drug Development Landscape

As immunotherapeutics in general - and immuno-oncology in particular - move to the forefront, the major oncology drug developers are beginning to align with specific therapeutic approaches, such as PARP and PD-1/PD-L1. Our analytics analysis of current active oncology trial data reveals these factors and how they are affecting the oncology drug development landscape. By combining data on the oncology drug delivery landscape with the relational power of analytics we've created a unique information resource that provides insight and clarity to market sector activity and competitive positioning within the oncology therapeutics space. By grouping and formatting information into visualizations that are easy to digest, readers gain a new and revealing perspective on the oncology drug development market.

Oncology Pipeline Analytics - What You Will Learn

  • Who are the leading developers in the current crop of oncology drugs in development? What are their activities and what is their position in therapeutic oncology markets?
  • What are the most frequently trailed therapeutic oncology drugs? What is the clinical strategy? How many trials are under way?
  • What are the major factors driving the oncology pipeline development market landscape?
  • What is the size of the oncology clinical trial market today, who are the market share leaders, and what will the market share look like in 2024?
  • How important are drug partnership relationships in the oncology drug development space?
  • Which indications are the focus of the highest level of clinical trial activity? How well-positioned are the leading oncology drug suppliers as the pace of oncology product introductions accelerates?
  • What are the significant economic, technology, and regulatory factors affecting the market?

Table of Contents

Executive Summary

Drug Development Challenges in Oncology Therapeutics

  • Biological Drugs
  • Biosimilars
  • Small Molecule Drugs

Leading Development-stage Oncology Therapeutics

  • atezolizumab
  • PD-1 & PD-L1
  • durvalumab
  • HDAC Inhibitors
  • nivolumab
  • BET Inhibitors
  • CAR-T cell therapy
  • Oncolytic Viruses
  • STAT3 Inhibitors
  • carbozantinib
  • Anti-LAG3 mAb
  • BTK Inhibitor
  • PARP Inhibitors

Oncology Clinical Trial Activity by Sponsor & Disease Segment

  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Head and Neck Cancer
  • Hematological Malignancies
  • Hepatic Cancer
  • Kidney Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Multiple Myeloma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Sarcomas
  • Skin Cancer
  • Solid Tumors
  • Other Cancers

Company Profiles

Tables, Charts and Visualizations

  • 1. Pipeline Activity by Cancer Segment (Bubble Chart)
  • 2. Sponsors of Active Oncology Trials (Heat Map)
  • 3. New BLAs by Application 2005-2017 (Dot Matric)
  • 4. Biological Drug Ecosystem (Global Map)
  • 5. atezolizumab - Trials by Disease Segment (Circle Grid)
  • 6. PD-1 / PD-L1 Inhibitors - Trials by Disease Segment (Circle Grid)
  • 7. PD-1 / PD-L1 Inhibitors - Active Trials by Sponsor (Pie Chart)
  • 8. PD-1 / PD-L1 Inhibitors - Active Trials by Disease Segment (Pie Chart)
  • 9. durvalumab - Trials by Disease Segment (Circle Grid)
  • 10. durvalumab - Active Trials by Sponsor (Pie Chart)
  • 11. durvalumab - Active Trials by Disease Segment (Pie Chart)
  • 12. HDAC Inhibitors - Active Trials by Disease Segment (Circle Grid)
  • 13. HDAC Inhibitors - Active Trials by Sponsor (Pie Chart)
  • 14. HDAC inhibitors - Active Trials by Disease Segment (Pie Chart)
  • 15. nivolumab - Active Trials by Disease Segment (Circle Grid)
  • 16. nivolumab - Active Trials by Disease Segment (Pie Chart)
  • 17. BET Inhibitors - - Active Trials by Disease Segment (Circle Grid)
  • 18. BET Inhibitors - Active Trials by Sponsor (Pie Chart)
  • 19. CAR-T cell therapy - Active Trials by Sponsor (Pie Chart)
  • 20. CAR-T cell therapy - Active Trials by Disease Segment (Pie Chart)
  • 21. Oncolytic Viruses - Active Trials by Disease Segment (Circle Grid)
  • 22. Oncolytic Viruses - Active Trials by Sponsor (Pie Chart)
  • 23. Oncolytic Viruses - Active Trials by Disease Segment (Circle Grid)
  • 24. STAT3 Inhibitors - Active Trials by Sponsor (Pie Chart)
  • 25. STAT3 Inhibitors - Active Trials by Disease Segment (Pie Chart)
  • 26. carbozantinib - Active Trials by Disease Segment (Pie Chart)
  • 27. Anti-LAG3 mAb - Active Trials by Sponsor (Pie Chart)
  • 28. Anti-LAG3 mAb - Active Trials by Disease Segment (Pie Chart)
  • 29. BTK Inhibitor - Active Trials by Sponsor (Pie Chart)
  • 30. BTK Inhibitor - Active Trials by Disease Segment (Pie Chart)
  • 31. PARP Inhibitors - Active Trials by Sponsor (Pie Chart)
  • 32. PARP Inhibitors - Active Trials by Disease Segment (Pie Chart)
  • 33. Bladder Cancer - Active Oncology Trials by Phase (Bar Graph)
  • 34. Brain Cancer - Active Trials by Disease Segment (Bar Graph)
  • 35. Breast Cancer - Active Trials by Disease Segment (Bar Graph)
  • 36. Colorectal Cancer - Active Trials by Disease Segment (Bar Graph)
  • 37. Gastric Cancer - Active Trials by Disease Segment (Bar Graph)
  • 38. Head and Neck Cancer - Active Trials by Disease Segment (Bar Graph)
  • 39. Hematological Malignancies - Active Trials by Disease Segment (Bar Graph)
  • 40. Hepatic Cancer - Active Trials by Disease Segment (Bar Graph)
  • 41. Kidney Cancer - Active Trials by Disease Segment (Bar Graph)
  • 42. Leukemia - Active Trials by Disease Segment (Bar Graph)
  • 43. Lung Cancer - Active Trials by Disease Segment (Bar Graph)
  • 44. Lymphoma - Active Trials by Disease Segment (Bar Graph)
  • 45. Multiple Myeloma - Active Trials by Disease Segment (Bar Graph)
  • 46. Ovarian Cancer - Active Trials by Disease Segment (Bar Graph)
  • 47. Pancreatic Cancer - Active Trials by Disease Segment (Bar Graph)
  • 48. Prostate Cancer - Active Trials by Disease Segment (Bar Graph)
  • 49. Sarcomas - Active Trials by Disease Segment (Bar Graph)
  • 50. Skin Cancer - Active Trials by Disease Segment (Bar Graph)
  • 51. Solid Tumors - Active Trials by Disease Segment (Bar Graph)
  • 52. Other Cancers - Active Trials by Disease Segment (Bar Graph)
  • 53. AbbVie - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 54. AbbVie - Active Oncology Trial Details (Table)
  • 55. AbbVie - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 56. Amgen - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 57. Amgen - Active Oncology Trial Details (Table)
  • 58. Amgen - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 59. AstraZeneca - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 60. AstraZeneca - Active Oncology Trial Details (Table)
  • 61. AsetraZeneca - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 62. Bayer Pharmaceuticals - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 63. Bayer Pharmaceuticals - Active Oncology Trial Details (Table)
  • 64. Bayer Pharmaceuticals - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 65. Boehringer Ingelheim - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 66. Boehringer Ingelheim - Active Oncology Trial Details (Table)
  • 67. Boston Biomedical - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 68. Boston Biomedical - Active Oncology Trial Details (Table)
  • 69. Bristol-Myers Squibb - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 70. Bristol-Myers Squibb - Active Oncology Trial Details (Table)
  • 71. Bristol-Myers Squibb - Active Oncology Trial Details (Table)
  • 72. Bristol Myers Squibb - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 73. Celgene - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 74. Celgene - Active Oncology Trial Details (Table)
  • 75. Celgene - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 76. Celldex Therapeutics - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 77. Celldex Therapeutics - Active Oncology Trial Details (Table)
  • 78. Eisai - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 79. Eisai - Active Oncology Trial Details (Table)
  • 80. Eli Lilly - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 81. Eli Lily - Active Oncology Trial Details (Table)
  • 82. Eli Lilly - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 83. EMD Serono- Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 84. EMD Serono - Active Oncology Trial Details (Table)
  • 85. EMD Serono - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 86. Exelxis - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 87. Exelixis - Active Oncology Trial Details (Table)
  • 88. Genentech - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 89. Genentech - Active Oncology Trial Details (Table)
  • 90. Genentech - Active Oncology Trial Details (Table)
  • 91. Genentech - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 92. Gilead Sciences - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 93. Gilead Sciences - Active Oncology Trial Details (Table)
  • 94. GlaxoSmithKline - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 95. GlaxoSmithKline - Active Oncology Trial Details (Table)
  • 96. Incyte - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 97. Incyte -
  • 98. Janssen Research & Development - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 99. Janssen Research & Development - Active Oncology Trial Details (Table)
  • 100. Janssen Research & Development - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 101. Karyopharm Therapeutics - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 102. Karyopharm Therapeutics - Active Oncology Trial Details (Table)
  • 103. Leap Therapeutics - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 104. Leap Therapeutics - Active Oncology Trial Details (Table)
  • 105. MacroGenics - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 106. MacroGenics - Active Oncology Trial Details (Table)
  • 107. MedImmune - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 108. MedImmune - Active Oncology Trial Details (Table)
  • 109. MedImmune - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 110. Merck - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 111. Merck - Active Oncology Trial Details (Table)
  • 112. Merck - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 113. Novartis Oncology - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 114. Novartis Oncology - Active Oncology Trial Details (Table)
  • 115. Novartis Oncology - Active Oncology Trial Details (Table)
  • 116. Novartis Oncology - Active Oncology Trial Details (Table)
  • 117. Novartis Oncology - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 118. Pfizer - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 119. Pfizer - Active Oncology Trial Details (Table)
  • 120. Pfizer - Number of Active Oncology Trials by Drug Class (Heat Map)
  • 121. Roche - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 122. Roche - Active Oncology Trial Details (Table)
  • 123. Seattle Genetics - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 125. Seattle Genetics - Active Oncology Trial Details (Table)
  • 126. Takeda Technology - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 127. Takeda Technology - Active Oncology Trial Details (Table)
  • 128. Tesaro - Clinical Trial Activity by Disease Segment (Bubble Chart)
  • 129. Tesaro - Active Oncology Trial Details (Table)
Back to Top
전화 문의
F A Q